Public invited to drop-in event to discuss Taunton river bathing site
A public drop-in event will take place at the COACH Community Hub in French Weir Park on Saturday, June 21 from 10am to 1pm, offering a chance to speak with experts about the River Tone, one of the UK's few officially designated river bathing sites.
The event will feature representatives from the Environment Agency, Wessex Water, Somerset Wildlife Trust, and Friends of French Weir Park.
Jim Flory of the Environment Agency said: "There are strict standards on what goes into rivers to protect wildlife and the natural ecology of our rivers.
"But the standards to protect human health are higher.
"A lot of investigation will be needed to uncover what sources of pollution feed into the River Tone.
"The public can help speed that up by eliminating the most obvious sources like picking up dog poo or looking after their septic tanks.
"This will free up people to focus on more serious issues."
The River Tone was officially designated as a bathing water site last year, meaning it is now subject to regular monitoring for bacteria such as E. coli and intestinal enterococci.
However, designation does not guarantee the water meets the standards required for safe swimming or other recreational activities.
The newly-formed steering group aims to tackle this problem by identifying and reducing pollution sources to improve water quality.
The Environment Agency will also be inspecting pipes and other infrastructure to identify sources of contamination.
Test results from ongoing monitoring will be published online at Swimfo, the Environment Agency's online platform.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Type 2 diabetes patients set for major shake-up in care
People with type 2 diabetes in England are to get the biggest shake up of care in a decade which could see them offered treatments, including jabs that aid weight-loss, sooner. The health service should move from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart attacks, according to new draft guidance from the National Institute for Health and Care Excellence (Nice). This includes making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, Nice said. It is estimated the change could save almost 22,000 lives once uptake reaches 90% of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
Yahoo
22 minutes ago
- Yahoo
At-home hepatitis C tests identify hundreds with the virus
The NHS has found 225 people with a silent but deadly virus as part of efforts to stamp out the disease and identify more victims of the infected blood scandal. Officials said more than 100,000 people have ordered at-home hepatitis C tests since the service was launched in May 2023. This includes 15,463 tests ordered in the week after the Infected Blood Inquiry published its final report on May 2024. Hepatitis C is a virus that is passed on through blood-to-blood contact and infects the liver. The disease is known as a 'silent killer' as some people can live with the virus for many years before realising that they are infected. But the delay in diagnosis can lead to irreparable liver damage, including scarring and cancer. If people test positive they can often be treated by taking antiviral tablets to fight off the virus for several weeks. People who test positive may also be offered a test to see whether any damage has been caused to the liver. Health officials said that 105,998 people have ordered an at-home NHS hepatitis C test online since the service was launched in 2023. Among those diagnosed under the NHS scheme so far, NHS England said that seven in 10 are from deprived communities. And it said that the most common risk factors reported by positive cases include injecting drug use, sharing needles and other drug paraphernalia and a history of prison. It is understood that only a very small number identified after ordering a test online had a positive result after receiving contaminated blood. In May this year NHS England also launched a system which means that people of a certain age who newly register with GP practices in England will be asked if they had a blood transfusion prior to 1996 in a bid to find more victims of the infected blood scandal. The Infected Blood Inquiry, which examined the scandal in depth, recommended that the health service should work to 'find the undiagnosed'. More than 30,000 people in the UK were infected with HIV and hepatitis C after they were given contaminated blood and blood products between the 1970s and early 1990s. And more than 3,000 people have died as a result while survivors are living with lifelong health implications. Professor Meghana Pandit, NHS national medical director, said 'We want to make it easier for people to access care before hidden viruses like hepatitis C cause people serious harm. 'The home testing service is available to everyone, and through targeted outreach to people at higher risk we are helping thousands avoid serious illness and reducing health inequalities in the process. 'If you or someone you know might be at risk, order a free and confidential test today via the NHS hepatitis C testing website – it could save your life.' Sema Mandal, deputy director for blood safety at UK Health Security Agency, said: 'Our data shows that the number of people with hepatitis C in England is continuing to fall, thanks to more people getting tested and taking treatment that clears the virus. 'I'm delighted to hear that 100,000 of the free self-testing kits have already been ordered via NHS online and this should further help us defeat this disease.' Rachel Halford, chief executive of The Hepatitis C Trust, said: 'Reaching 100,000 home tests is an incredible milestone as we push closer towards the elimination of hepatitis C. 'This option of home testing allows people with any concerns to get a free, confidential test without the need to attend a clinic. For many hesitant to access health services, this can act as a lifeline. 'While injecting drug use remains a key risk factor, it is equally important to remember those affected by the infected blood scandal – the most devastating treatment disaster in the history of the NHS. 'If you received a blood transfusion or blood products before 1996, we strongly encourage you to order a test. Even for peace of mind alone, it could be invaluable. Today's treatments are highly effective, simple to take, and come with minimal side effects.'
Yahoo
an hour ago
- Yahoo
Largest study on youth vaping suggests it is a gateway to smoking
Children who vape are more likely to go on to be smokers, be diagnosed with asthma and have poor mental health, a new analysis suggests. The largest global review on vaping in young people found 'consistent evidence' that children who vape are three times more likely to go on to become smokers. The study also pointed to links between vaping and increased odds of respiratory illness and substance abuse including drinking and marijuana use. Experts from the University of York and the London School of Hygiene and Tropical Medicine (LSHTM) analysed all available reviews on youth vaping – also known as an umbrella review. This including 56 reviews on 384 studies. Some 21 of these looked at use of e-cigarettes among young people and later cigarette smoking. Not only were vapers more likely to smoke in later life, they were also more likely to smoke more frequently and intensely, experts said. Researchers also tracked breathing problems linked to youth vaping. The data suggested an increased risk among young people who vape of developing asthma or asthma exacerbation. Other harmful outcomes linked to youth vaping included pneumonia, bronchitis, lower total sperm counts,dizziness, headaches and migraines. There was also a link identified between depression and suicidal thoughts among young vapers. Writing in the journal Tobacco Control, the authors said the data available 'consistently indicated a significant association between e-cigarette use and later cigarette smoking in young people'. They said that it is difficult to 'infer causality' from their review, but said the 'repeated strong associations in prospective cohort studies are consistent with a causal relationship'. Dr Su Golder, associate professor in health science at the University of York, said: 'The consistency in the evidence is striking. 'Across multiple studies, young people who use e-cigarettes are more likely to smoke in the future. These findings support stronger public health measures to protect teens from the risks associated with vaping.' Dr Greg Hartwell, clinical assistant professor at LSHTM, said: 'We found consistent evidence around transitions to smoking which of course, in turn, opens the door to the multitude of harms that conventional cigarettes bring. 'As the UK Government's chief medical officer states, marketing vapes to children is always unacceptable, and our review shows exactly why further restrictions on the tobacco industry, who control the vaping market, are so important.' Dr Rebecca Glover, senior author of the study, assistant professor at LSHTM, added: 'Vaping is having a detrimental impact on the health of young people globally and vaping appears to be a gateway to other substances. 'Our study provides the strongest evidence to date that young people globally face a serious range of physical and psychological harms from vaping and are at higher risk of transitioning to smoking.' In June the ban on disposable vapes was introduced in a bid to curb their use among young people. The crackdown on the devices, also known as single-use vapes, makes it illegal for any retailer – ranging from corner shops to supermarkets – to sell them. The ban applies to both online and in-store sales across England, Scotland, Wales and Northern Ireland, and all disposable vapes whether or not they contain nicotine. Retailers are still allowed to sell reusable vapes. Commenting on the study, Jamie Strachan, operations director at VPZ, said: 'Vaping is intended solely for existing adult smokers as a less harmful alternative to combustible tobacco. It should never be marketed to, sold to, or used by children and non-smokers. 'VPZ supports strict regulation that prevents under-18s from obtaining vaping products.' Dr James Murphy, director of science and research at British American Tobacco (BAT), said: 'There is little evidence that vaping is a gateway to smoking. In fact, it has helped millions of adults move away from cigarettes. 'While not risk-free, experts agree it poses only a fraction of the risks of smoking. 'Smart regulation that gives adults access to better alternatives, while enforcing high standards and preventing under-age use, is vital to achieving the UK's smoke-free goal.'
